These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 15764279)

  • 1. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
    Halland A; Jønler M; Pedersen KV
    Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer in men using testosterone supplementation.
    Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
    J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostatic complications of testosterone replacement therapy.
    Jackson JA; Waxman J; Spiekerman AM
    Arch Intern Med; 1989 Oct; 149(10):2365-6. PubMed ID: 2679476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone therapy in the ageing male: what about the prostate?
    Schultheiss D; Machtens S; Jonas U
    Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer after exogenous testosterone treatment for impotence.
    Loughlin KR; Richie JP
    J Urol; 1997 May; 157(5):1845. PubMed ID: 9112543
    [No Abstract]   [Full Text] [Related]  

  • 7. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
    Morales A; Black AM; Emerson LE
    BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring androgen replacement therapy: testosterone and prostate safety.
    Morales A
    J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer following testosterone replacement in Klinefelter syndrome.
    Bydder SA; Joseph DJ; Weinstein S; Stuckey BG
    ANZ J Surg; 2007; 77(1-2):93-4. PubMed ID: 17295832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
    Kaplan AL; Hu JC
    Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid androgen cycling as treatment for patients with prostate cancer.
    Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
    Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of androgen supplementation therapy on the prostate.
    Kaufman JM
    Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F; Ozyigit G; Selek U; Karabulut E
    Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
    Morgunov LIu; Vertkin AL; Pushkar' DIu
    Urologiia; 2007; (5):49-51. PubMed ID: 18254226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer in a hypogonadal male receiving androgen supplementation.
    Ferri M; Norman RW
    Can J Urol; 2000 Jun; 7(3):1055-6. PubMed ID: 11118282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
    Gould DC; Kirby RS
    Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.